CSPC Pharmaceutical Group Limited
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the manufacture and sale of pharmaceutical products in Mainland China, other Asian regions, Europe, North America, and internationally. It operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. The company provides NBP soft capsules and injections for acute ischemic stroke; Oulaining cap… Read more
CSPC Pharmaceutical Group Limited (CSPCY) - Net Assets
Latest net assets as of June 2025: $34.86 Billion USD
Based on the latest financial reports, CSPC Pharmaceutical Group Limited (CSPCY) has net assets worth $34.86 Billion USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($46.00 Billion) and total liabilities ($11.14 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $34.86 Billion |
| % of Total Assets | 75.79% |
| Annual Growth Rate | 13.75% |
| 5-Year Change | 23.71% |
| 10-Year Change | 402.91% |
| Growth Volatility | 125.71 |
CSPC Pharmaceutical Group Limited - Net Assets Trend (2003–2024)
This chart illustrates how CSPC Pharmaceutical Group Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for CSPC Pharmaceutical Group Limited (2003–2024)
The table below shows the annual net assets of CSPC Pharmaceutical Group Limited from 2003 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $33.87 Billion | -0.07% |
| 2023-12-31 | $33.89 Billion | +11.82% |
| 2022-12-31 | $30.31 Billion | -7.57% |
| 2021-12-31 | $32.79 Billion | +19.78% |
| 2020-12-31 | $27.38 Billion | +24.40% |
| 2019-12-31 | $22.01 Billion | +41.70% |
| 2018-12-31 | $15.53 Billion | +20.62% |
| 2017-12-31 | $12.87 Billion | +45.93% |
| 2016-12-31 | $8.82 Billion | +31.01% |
| 2015-12-31 | $6.73 Billion | +18.04% |
| 2014-12-31 | $5.70 Billion | +18.42% |
| 2013-12-31 | $4.82 Billion | -9.17% |
| 2012-12-31 | $5.30 Billion | +581.94% |
| 2011-12-31 | $777.73 Million | +36.52% |
| 2010-12-31 | $569.69 Million | -87.86% |
| 2009-12-31 | $4.69 Billion | +16.28% |
| 2008-12-31 | $4.04 Billion | -25.60% |
| 2007-12-31 | $5.42 Billion | +104.77% |
| 2006-12-31 | $2.65 Billion | +2.41% |
| 2005-12-31 | $2.59 Billion | +6.99% |
| 2004-12-31 | $2.42 Billion | +6.86% |
| 2003-12-31 | $2.26 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to CSPC Pharmaceutical Group Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2334408000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $23.34 Billion | 72.35% |
| Common Stock | $11.03 Billion | 34.19% |
| Total Equity | $32.26 Billion | 100.00% |
CSPC Pharmaceutical Group Limited Competitors by Market Cap
The table below lists competitors of CSPC Pharmaceutical Group Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Tower Semiconductor Ltd
NASDAQ:TSEM
|
$14.48 Billion |
|
CK Asset Holdings Limited
PINK:CNGKY
|
$14.49 Billion |
|
ASICS Corporation
PINK:ASCCF
|
$14.51 Billion |
|
Standard Bank Group Ltd PK
PINK:SGBLY
|
$14.52 Billion |
|
China Northern Rare Earth Group High-Tech Co Ltd
SHG:600111
|
$14.43 Billion |
|
Sieyuan Electric Co Ltd
SHE:002028
|
$14.43 Billion |
|
NN Group N.V
PINK:NNGPF
|
$14.43 Billion |
|
Bureau Veritas SA
PINK:BVVBY
|
$14.42 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CSPC Pharmaceutical Group Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 33,203,208,000 to 32,264,695,000, a change of -938,513,000 (-2.8%).
- Net income of 4,605,334,000 contributed positively to equity growth.
- Dividend payments of 3,441,006,887 reduced retained earnings.
- Share repurchases of 2,336,261,310 reduced equity.
- Other comprehensive income increased equity by 1,410,661,000.
- Other factors decreased equity by 667,178,803.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $4.61 Billion | +14.27% |
| Dividends Paid | $3.44 Billion | -10.66% |
| Share Repurchases | $2.34 Billion | -7.24% |
| Other Comprehensive Income | $1.41 Billion | +4.37% |
| Other Changes | $-667.18 Million | -2.07% |
| Total Change | $- | -2.83% |
Book Value vs Market Value Analysis
This analysis compares CSPC Pharmaceutical Group Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.24x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.86x to 0.24x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2003-12-31 | $3.07 | $2.64 | x |
| 2004-12-31 | $3.26 | $2.64 | x |
| 2005-12-31 | $3.50 | $2.64 | x |
| 2006-12-31 | $3.59 | $2.64 | x |
| 2007-12-31 | $1.94 | $2.64 | x |
| 2008-12-31 | $5.36 | $2.64 | x |
| 2009-12-31 | $6.17 | $2.64 | x |
| 2010-12-31 | $0.76 | $2.64 | x |
| 2011-12-31 | $0.37 | $2.64 | x |
| 2012-12-31 | $2.41 | $2.64 | x |
| 2013-12-31 | $2.06 | $2.64 | x |
| 2014-12-31 | $2.26 | $2.64 | x |
| 2015-12-31 | $2.56 | $2.64 | x |
| 2016-12-31 | $3.14 | $2.64 | x |
| 2017-12-31 | $4.38 | $2.64 | x |
| 2018-12-31 | $5.01 | $2.64 | x |
| 2019-12-31 | $6.91 | $2.64 | x |
| 2020-12-31 | $8.86 | $2.64 | x |
| 2021-12-31 | $10.64 | $2.64 | x |
| 2022-12-31 | $9.99 | $2.64 | x |
| 2023-12-31 | $11.19 | $2.64 | x |
| 2024-12-31 | $10.99 | $2.64 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CSPC Pharmaceutical Group Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 14.27%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 14.92%
- • Asset Turnover: 0.70x
- • Equity Multiplier: 1.38x
- Recent ROE (14.27%) is below the historical average (23.21%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2003 | 23.70% | 20.29% | 0.74x | 1.58x | $309.85 Million |
| 2004 | 10.83% | 9.98% | 0.52x | 2.08x | $19.95 Million |
| 2005 | 6.29% | 4.90% | 0.59x | 2.16x | $-95.96 Million |
| 2006 | 0.58% | 0.43% | 0.67x | 1.99x | $-249.47 Million |
| 2007 | 31.19% | 9.56% | 0.77x | 4.23x | $303.45 Million |
| 2008 | 20.91% | 13.77% | 0.86x | 1.76x | $432.17 Million |
| 2009 | 18.81% | 13.81% | 0.78x | 1.74x | $400.35 Million |
| 2010 | 114.13% | 9.67% | 4.45x | 2.65x | $584.48 Million |
| 2011 | 24.56% | 3.16% | 3.06x | 2.54x | $111.87 Million |
| 2012 | 32.83% | 52.15% | 0.31x | 2.05x | $1.21 Billion |
| 2013 | 13.05% | 9.78% | 0.83x | 1.62x | $177.76 Million |
| 2014 | 15.70% | 11.58% | 0.88x | 1.54x | $368.26 Million |
| 2015 | 19.06% | 14.62% | 0.85x | 1.54x | $662.76 Million |
| 2016 | 20.78% | 16.98% | 0.84x | 1.46x | $976.07 Million |
| 2017 | 18.08% | 17.92% | 0.72x | 1.41x | $1.03 Billion |
| 2018 | 21.37% | 17.38% | 0.80x | 1.55x | $1.71 Billion |
| 2019 | 22.40% | 18.46% | 0.85x | 1.43x | $2.56 Billion |
| 2020 | 19.49% | 17.42% | 0.83x | 1.35x | $2.51 Billion |
| 2021 | 21.63% | 20.11% | 0.80x | 1.34x | $3.70 Billion |
| 2022 | 23.16% | 19.69% | 0.84x | 1.40x | $3.92 Billion |
| 2023 | 17.69% | 16.98% | 0.75x | 1.39x | $2.55 Billion |
| 2024 | 14.27% | 14.92% | 0.70x | 1.38x | $1.38 Billion |
Industry Comparison
This section compares CSPC Pharmaceutical Group Limited's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $308,328,125,500
- Average return on equity (ROE) among peers: 18.93%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CSPC Pharmaceutical Group Limited (CSPCY) | $34.86 Billion | 23.70% | 0.32x | $14.45 Billion |
| AbbVie Inc (ABBV) | $13.10 Billion | 35.24% | 10.50x | $390.88 Billion |
| Astellas Pharma Inc (ALPMF) | $1.06 Trillion | 7.80% | 0.36x | $16.93 Billion |
| Amgen Inc (AMGN) | $20.39 Billion | 20.58% | 0.79x | $196.91 Billion |
| Amarin Corporation PLC (AMRN) | $28.90 Million | 14.19% | 0.23x | $303.32 Million |
| AstraZeneca PLC (AZN) | $48.72 Billion | 21.05% | 1.34x | $296.35 Billion |
| Bayer AG (BAYZF) | $31.90 Billion | 14.21% | 1.58x | $21.61 Billion |
| Biogen Inc (BIIB) | $325.20 Million | 9.96% | 0.10x | $26.81 Billion |
| Bristol-Myers Squibb Company (BMY) | $5.08 Billion | 14.69% | 0.67x | $121.36 Billion |
| Chugai Pharmaceutical Co. Ltd (CHGCF) | $1.90 Trillion | 20.37% | 0.16x | $28.30 Billion |
| Cosmo Pharmaceuticals N.V (CMOPF) | $220.16 Million | 31.22% | 0.10x | $529.97 Million |